To investigate the effects of intravenous iloprost on pulmonary artery hypertension (PAH) in infants undergoing congenital heart surgery.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is an important cause of postoperative morbidity and mortality in infants undergoing congenital cardiac operations [1] [2] [3] . This life-threatening condition is largely due to a left-to-right shunt, which triggers a series of events in the vascular function of the pulmonary arteries leading to heart failure [4] . The incidence of PAH crisis decreases after correction of intracardiac defects such ventricular and atrial septal defects. However, this event can be evident after congenital cardiac operations in infants with PAH. The recent guideline for the diagnosis and treatment of pulmonary hypertension in 2009 recommends the use of different therapeutic agents, including calcium channel blockers, endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase-5 inhibitors [1] . Iloprost is a prostacyclin analogue and can be used to provide vascular relaxation and decreased pulmonary vascular resistance (PVR).
It increases the intracellular cyclic adenosinemonophosphate (cAMP) level and inhibits myosin kinases, resulting in vascular relaxation. Currently, iloprost is generally used as an inhalant agent in congenital cardiac surgery [5] [6] [7] [8] [9] . Inhalation is a selective way of delivery for iloprost to the pulmonary vasculature and avoids systemic complications such as hypotension. Little research has been done, however, on intravenous use of iloprost after congenital cardiac operations. We therefore evaluated the effects of intravenous iloprost for the management of postoperative PAH after congenital heart surgery.
heart diseases. The study was conducted as a prospective randomized clinical study. Twenty-seven infants who had severe PAH with significant left-to-right shunt including non-restrictive ventricular septal defects (VSDs; n = 17) or complete atrioventricular septal defects (AVSDs; n = 10) were enrolled in the study. Patients with restrictive septal defects, multiple VSDs, pulmonary stenosis and additional intracardiac or aortic arch anomalies were excluded. In all patients, PAH was suspected by clinical and Doppler echocardiographic examinations preoperatively. Echocardiographic studies showed severe PAH in patients with systolic pulmonary artery (PA) pressure above 50 mmHg and mean PA pressure (MPAP) above 25 mmHg at rest in the absence of other causes of precapillary pulmonary hypertension, such as pulmonary hypertension due to pulmonary disease [1] . Before surgery, pulmonary artery pressures were directly measured and confirmed with catheterization. Preoperative characteristics of patients are presented in Table 1 .
Randomization was performed before surgery using sealed envelopes. Patients were divided into two groups: a control group (n = 12) and a study group (n = 15), in which iloprost trometamol infusion (2.0 ng/kg/min) (BerliMed S.A., Madrid, Spain) was delivered intravenously after weaning from cardiopulmonary bypass [10] . Intravenous iloprost was started in the operation theatre and was delivered continuously during the postoperative intensive care unit (ICU) follow-up.
General anaesthesia was induced with intravenous midazolam (0.1-0.3 mg/kg), fentanyl (10 µg/kg) and vecuronium (0.2 mg/kg). Anaesthesia was maintained with fentanyl (5 µg/g/h), midazolam (0.1 mg/g/h) and isoflurane. A single surgeon performed all operations with the same repair technique. Operations were performed through a median sternotomy with cardiopulmonary bypass. Myocardial protection was achieved via the intermittent delivery of antegrade isothermic blood cardioplegic solution. A right atrial incision was the routine approach for exploration of AVSDs and achievement of optimal surgical exposure during repair. A Dacron patch was used for closure of VSDs, whereas a 2-patch technique was used for the repair of AVSDs. Operations were completed uneventful.
All patients had surgically implanted single-lumen 3.5-F catheters (Ombilicath, Prodimed, Le Plessis Bouchard, France) within the pulmonary artery for continuous monitoring of PA pressure. The catheters were implanted using the Seldinger technique before weaning from cardiopulmonary bypass. A pericardial pledgeted 5-0 Prolene purse-string suture was first placed in the muscular part of the right ventricular outflow tract below the pulmonary annulus. Catheters were introduced over a soft guide wire through the purse-string suture. The tips of the catheters were placed 1 cm below the pulmonary valve, and sutures around the catheters were secured gently. The proximal ends of the catheters were passed through the skin and connected to the pressure transducer for simultaneous monitoring of pulmonary blood pressure. These catheters were removed 72 h postoperatively in the ICU.
All patients were sedated for 24 h postoperatively. They were ventilated with 100% oxygen after weaning from cardiopulmonary bypass, and the fraction of inspired oxygen was decreased according to the level of systemic oxygen saturation in blood gas analyses in the follow-up. The CO 2 level was maintained at 35-40 mmHg, and positive end-expiratory pressure was delivered at 5 mmHg. A pulmonary hypertensive crisis was defined as an increase in PAP to exceed 70% of systemic blood pressure, a decrease in systemic blood pressure and a decrease in S p O2 . When PAH crisis occurred, nitric oxide (NO) inhalation was started immediately at a dose of 20 parts per million ( ppm) using a commercially available NO delivery and monitoring system (NOxBOXO2, Bedfont Scientific Ltd, Maidstone, England).
The primary outcome of this study was to assess the effect of intravenous iloprost on the incidence of PAH. In the early postoperative period, systolic PA, diastolic and mean pressures were continuously monitored and recorded at 6, 12, 24, 36, 48 and 72 h. Simultaneously, arterial blood pressures were recorded. All patients underwent a transthoracic echocardiography (TTE) at 1 and 7 days during their hospital stay and at 30 days after hospital discharge. During the 30-day follow-up visit, vital signs were also recorded. Systolic PA and diastolic pressures were recorded, and ventricular function was evaluated. Systolic PA and PA/systemic blood pressure ratio were calculated.
Clinical data recorded during the follow-up period included mortality after surgery, postoperative PAH crisis, need for NO inhalation, ventilation time, reintubation rate, new-onset arrhythmia, lactate levels, prolonged need for an inotropic agent (>24 h), reoperation, ICU stay and hospital stay. TTE was used for the measurement of systolic PA pressure and MPAP and ventricular function preoperatively and postoperatively on Days 1, 7 and 30. Echocardiographic evaluation was performed using the Vivid® S5 (GE Healthcare; Wausheka, WI, USA) ultrasonography system. Standard parasternal long-axis, short-axis and apical four-and twochamber views were obtained. The cardiologists were blinded to the study protocol.
Systolic PA pressure was calculated from the tricuspid regurgitation velocity and pressure gradient and estimated right atrial pressure as follows [1] :
Systolic PA pressure ¼ tricuspid regurgitation pressure gradient þ estimated right atrial pressure
The MPAP [11] and systolic PA/systemic blood pressure ratio were calculated using the formulas below. Systemic blood pressure was 
RESULTS
Preoperative characteristics were similar between the two groups ( Table 1) . Cardiopulmonary bypass and aortic clamping times were similar (P = 0.33 and P = 0.26, respectively). The age ranges of the infants in the study and control groups were 4-15 and 4-12 months, respectively. In the study group, only 2 patients were 4 months of age, and the others were more than 6 months old. In the control group, only 1 patient was 4 months old and the others were more than 6 months old. Operations were completed uneventfully in all patients. No procedure-related or postoperative deaths occurred.
Postoperative data are presented in Table 2 . PAH crisis developed in 2 of 12 patients (16.6%) in the control group ( postoperatively at 11 and 82 h) and 4 of 15 (26.7%) patients in the study group ( postoperatively at 12 h in 2 patients and at 42 and 82 h in the other patients). There was no significant difference between the groups in the incidence of postoperative PAH crisis (P = 0.53). PAH crises were controlled immediately by deep sedation, muscle paralysis and NO inhalation therapy. Duration of NO delivery was less than 48 h and was similar between the groups (P = 0.63). Mean mechanical ventilation time was 4.4 ± 6.2 (range; 1.2-4.7) days and 4.1 ± 5.7 (range; 0.8-7.0) days in the control and study groups (P = 0.47), respectively. The lengths of stay in the ICU (8.3 ± 7.2 vs 7.3 ± 6.4 days, P = 0.40) and hospital (15.0 ± 7.5 vs 15.3 ± 9.3 days, P = 0.98) were similar between the groups. Prolonged delivery of inotropic agents was needed in 5 (41.6%) patients in the control group and 7 (46.6%) patients in the study group (P = 0.79). Reintubation rates were similar between the groups (33.3 vs 26.7%, P = 0.70).
Post-procedure, intraoperative measurements showed that the PA/systemic pressure ratio of patients after cardiopulmonary bypass was less than 0.4 in both the control and study groups (0.3 ± 0.1 vs 0.3 ± 0.1, P = 0.72). In groups, PA/systemic pressure ratios were significantly decreased immediately after correction of intracardiac defects (P < 0.05). Table 3 presents a comparison of systolic PA/systemic pressure ratios at 6, 12, 24, 36, 48 and 72 h postoperatively. Postoperative courses of systolic PA pressure and MPAP are presented in Figs. 1 and 2 . During iloprost infusion, systolic PA pressure and MPAP did not decline at all for the postoperative 72 h even in the infusion group. And, no significant difference of systolic PA pressure and MPAP for the postoperative 72 h between the two groups was observed. Considering these results, the primary efficacy end-point did not reach significant differences between the two groups in these circumstances. Although a significant change in the systolic PA/systemic blood pressure ratios was seen postoperatively compared with the preoperative values, no significant difference was noted between the groups at each postoperative follow-up time (P > 0.05). In addition, no significant change in the PA/systemic pressure ratios occurred in both groups postoperatively (P > 0.05). Table 4 presents the peak systolic PA and systemic blood pressures after surgery. No significant changes in the highest PA pressure and PA/systemic pressure ratio were observed. The highest PA/systemic pressure ratio was 0.5 ± 0.2 in the control group and 0.5 ± 0.1 in the study group (P = 0.98). The highest systolic PA pressures in the control and study groups were observed at 43.9 ± 27.1 and 52.2 ± 32.8 h postoperatively, respectively (P = 0.48).
Echocardiographic follow-up values of MPAP at 1, 7 and 30 days postoperatively are presented in Table 5 . A significant and progressive decrease in MPAPs was seen in the control (P = 0.001) and study (P = 0.0001) group at each follow-up examination. However, no significant change in MPAPs using TTE was observed on Days 1, 7 or 30 postoperatively between the groups (P > 0.05). The Tukey multiple comparison test showed a significant decrease in MPAPs in the control and study groups during each follow-up visit (P < 0.05; Table 6 ). In the control group, postoperative MPAP on postoperative day 1 was significantly higher than PA pressures on postoperative day 7 (P = 0.027) and 30 (P = 0.002). The MPAP at 7 days was significantly higher than that at 30 days postoperatively (0.042). In the study group, MPAP at postoperative day 1 was significantly higher than PA pressures at postoperative day 7 (P = 0.049) and 30 (P = 0.0001). The MPAP at 7 days was significantly higher than that at 30 days postoperatively (P = 0.002).
At baseline and at the end of the infusions of iloprost, some variables for oxygenation were studied. In the study group, oxygenation index, Pa O2 and mixed venous oxygen saturation were 12.5 ± 0.9 versus 12.0 ± 0.7 (P > 0.05), 78.6 ± 10.4 versus 82.0 ± 8.9 (P > 0.05) and 59.2 ± 4.2 versus 60.1 ± 0.9 (P > 0.05), respectively. In the control group, these values were 13.5 ± 0.4 versus 12.3 ± 0.5 (P > 0.05), 88.6 ± 8.2 versus 90.7 ± 4.6 (P > 0.05) and 61.5 ± 3.0 versus 58.3 ± 0.6 (P > 0.05), respectively. We observed no difference between the measurements in both groups.
There was no catheter-related complication such as pericardial effusion or tamponade after removal of the PA catheters.
DISCUSSION
Pulmonary arterial hypertension can be fatal in the early postoperative follow-up of patients with PAH, especially in infancy. The increase in PVR is related to different mechanisms, including vasoconstriction, proliferative and obstructive remodelling of the pulmonary vessel wall, inflammation and thrombosis. With regard to aetiology, intracardiac shunts and the use of cardiopulmonary bypass leads to the development of postoperative PAH crisis associated with iatrogenic injury or transient dysfunction of the pulmonary endothelium [12] . Systemic inflammatory response and associated impaired endothelium-dependent vasodilatation may present with high pulmonary blood pressure leading to PAH [13] .
Pulmonary artery vascular resistance generally decreases after correction of intracardiac shunts such as AVSDs and VSDs. Nevertheless, PAH crisis can develop immediately after operations and leads to disturbance of alveolar gas exchange, right ventricular failure and fatal events in the early postoperative period [14] . Endothelial dysfunction leads to impaired production of vasodilator and antiproliferative agents such as NO and prostacyclin. Besides, overexpression of vasoconstrictor substances such as thromboxane A2 and endothelin-1 disturbs vascular function. Vasodilatory mediators may decrease the risk for PAH after congenital cardiac operations. Understanding the pathogenesis of PAH has led to the use of different agents, including endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase-5 inhibitors [1] . Iloprost is a prostacyclin analogue (a derivative of prostaglandin-I2), which is metabolized from endogenous arachidonic acid through the cyclooxygenase pathway. It increases the intracellular cAMP level and inhibits myosin kinases. This results in vascular relaxation and decreased PVR. Inhalation of iloprost is widely used in the management of PAH crisis after congenital heart operations [1, [5] [6] [7] [8] [9] . Although the current guidelines recommend the use of iloprost in the treatment of PAH [1] , there has been no study comparing the perioperative effect of intravenous iloprost in infants at risk of PAH following repair of a congenital heart defect. The hypothesis of this study was to investigate if intravenous iloprost has a significant effect on PVR after congenital heart surgery. The follow-up of PA pressures in the control and study groups showed a significant decrease after operations. In all patients, systolic and mean pulmonary artery pressures significantly decreased after operations. During iloprost infusion, systolic PA pressure and MPAP did not decline at all for the postoperative 72 h even in the infusion group. No significant difference of systolic PA pressure and MPAP for the postoperative 72 h between the two groups was observed. The incidence of PAH crisis and postoperative complications was similar between the two groups. However, the primary efficacy end-point did not reach significant differences between the two groups in these circumstances. Considering these results, we concluded that the use of intravenous iloprost added no additional benefit to conventional management of postoperative pulmonary hypertension.
Despite advances in surgical techniques and postoperative management of patients, PAH continues to be a considerable problem for paediatric anaesthesiologists and cardiac surgeons. Administration of sedation/analgesia or general anaesthesia is recommended in postoperative PAH in infants and children [15] . This approach provides adequate analgesia while minimizing increases in PVR in the early postoperative period of congenital heart surgery. In our clinical practice, patients with preoperative PAH are deeply sedated during the immediate postoperative period, and a careful weaning period is then allowed after stabilization of vital parameters and cardiac function. In this study, PA pressures significantly decreased postoperatively and patients were followed with PA/Ao pressure ratios within normal ranges after operations. However, 8% of patients in the control group and 13% of patients in the study group developed PAH crisis and NO inhalation was used. The incidence of PAH crises in the first 24 h postoperatively was statistically similar between the groups. In the literature, reports on the additional benefit of intravenous iloprost over sedation are limited [11, 16] .
The most common cause for PAH in childhood is congenital heart disease [16, 17] . Left-to-right intracardiac shunts in paediatric patients increase pulmonary flow and pressure and eventually lead to PAH. Although surgical correction of intracardiac shunts may improve the degree of vascular resistance and PA pressure may normalize after surgery, the risk of PAH crisis is a potential complication in the ICU. In the early postoperative period, clinical management generally involves sedation, avoidance of hypoxia, maintenance of a CO 2 level of 35-40 mmHg and delivery of positive end-expiratory pressure of 5 mmHg. Besides, the avoidance of cardiac dysfunction, tamponade, pulmonary oedema and pleural complications such as pneumothorax is important. In our experience, we observed that these preventive measures were effective in the management of patients. No mortality occurred, and no major events such as prolonged ventilation, sedation and inotropic support or extracorporeal cardiopulmonary life support developed. However, the reintubation rate was relatively higher than the usual postoperative course. This might be related to the presence of patients with Down syndrome in both groups. Reintubation was needed in 3 and 2 patients in the study and control groups, respectively. A heterogeneous patient population including patients with Down syndrome was also a limitation of this study.
Postoperative left ventricular dysfunction, residual left-to-right shunts and increased capillary wedge pressure leading to pulmonary parenchymal and airway oedema are also potential risk factors for PAH crisis. In all patients, echocardiographic examinations were performed routinely. During the operations, transoesophageal echocardiography was performed after cardiopulmonary bypass, and cardiac functions and residual defects were evaluated. In the postoperative course, TTE was performed routinely in daily practice in the ICU. This approach is our routine clinical approach in patients with PAH as well as other paediatric cases. In patients of our study, we observed that left ventricular function was preserved, and there were no residual intracardiac defects or shunts. Atrioventricular valves were also competent.
The use of prostacyclin and its analogues provides beneficial effects in the management of PAH [1, [5] [6] [7] [8] [9] 18] . These agents can be delivered intravenously or subcutaneously, or by inhalation. Previous studies have shown that iloprost inhalation was found to be associated with very few systemic effects [19] . It was a selectively delivered medication for pulmonary vasculature without cardiac dysfunction or decreased vascular resistance. However, studies on the intravenous use of iloprost are limited in patients with secondary PAH due to congenital heart disease [1, 5-8, 18, 19] . Some authors may argue about the systemic effect of intravenous iloprost on peripheral vascular resistance. In our study, we observed that intravenous iloprost decreased both systemic and pulmonary vascular pressure, but these effects could be reversed with successful management by using vasoconstrictor agents such as noradrenaline. Although there is no consensus on the optimal dose of intravenous iloprost, it was used in our study at a dose of 2.0 ng/kg/min. This dose regimen was previously used by Higenbottam et al. [10] who showed its efficacy in the management of adult patients with PAH.
In congenital heart diseases, deterioration of oxygenation occurs in the patients with pulmonary hypertension. The oxygenation parameters reflect, at least in part, the degree of severity of illness. Besides the haemodynamic parameters, parameters of oxygenation including oxygen index, Pa O2 , AaDO 2 or mixed venous oxygen saturation at baseline and at the end of the infusions of iloprost were evaluated. At baseline and at the end of the infusions of iloprost, there was no difference in each group before and at the end of iloprost infusion. We may speculate that the intravenous iloprost has no additional efficacy on oxygenation in patients with pulmonary hypertension after correction of intracardiac defects.
NO inhalation is increasingly used for the treatment of PAH after surgical repair of congenital heart defects. One of the main complications of NO use is deterioration of oxygenation following withdrawal of NO inhalation. This is known as 'rebound effect' and can be defined as a 5% decrease in oxygenation saturation within 4 h after NO withdrawal. Clinically, significant increases in PVR have been noted upon acute withdrawal of NO inhalation. This is related to the fine balance between the level of endothelin-1 and endogenous NO synthase activity [20, 21] . Previously, Hermon et al. [20] reported that intravenous delivery of iloprost before NO use and during its withdrawal might be able to mitigate the rebound effect. In our study, 6 infants were treated with NO inhalation for PAH crisis, and 4 of them were receiving intravenous iloprost. We did not observe such an event in these patients. This event should be in the armamentarium of clinicians who are involved in the management of PAH and congenital heart surgery.
Limitations include the small number of study groups and the heterogeneous population. In both groups, there are some patients with Down syndrome, which can be a potential risk factor for increased pulmonary complications after operations. Besides, 3 patients in each group were less than 6 months of age. This might affect the homogeneity of the groups in terms of relatively high incidence of pulmonary vascular complications with time after 6 months.
In conclusion, this study revealed that intravenous iloprost demonstrated no additional benefit over the conventional management of infants with PAH. Although PA pressures decreased after repair of intracardiac pathologies, the primary efficacy endpoint did not reach significant differences between the two groups in terms of the incidence of PAH. This study does, however, demonstrate that intravenous iloprost can be used safely after congenital heart operations without significant haemodynamic side effects such as hypotension.
